It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Takeda will seek an external partner to leverage its cell therapy platform technologies
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated
